Presentation is loading. Please wait.

Presentation is loading. Please wait.

Birch pollen immunotherapy results in long-term loss of Bet v 1–specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies 

Published byYulia Darmadi Modified over 5 years ago

Similar presentations

Presentation on theme: "Birch pollen immunotherapy results in long-term loss of Bet v 1–specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies "— Presentation transcript:

1 Birch pollen immunotherapy results in long-term loss of Bet v 1–specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies  Christian Möbs, PhD, Henrik Ipsen, MSc, Lea Mayer, DDS, Caroline Slotosch, MD, Arnd Petersen, PhD, Peter A. Würtzen, PhD, Michael Hertl, MD, Wolfgang Pfützner, MD  Journal of Allergy and Clinical Immunology  Volume 130, Issue 5, Pages e6 (November 2012) DOI: /j.jaci Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 ELISpot analysis of Bet v 1–specific IL-5–, IFN-γ–, and IL-10–producing T cells during a 54-month (m0-m54) observation period including SIT with birch pollen extract and a follow-up phase after cessation of treatment (post-SIT). Median values are indicated by black lines. Birch pollen seasons are highlighted in gray. Discontinuities by dashed lines mark nonexistent data. Differences between initiation of SIT and during/after SIT were analyzed by using the nonparametric Wilcoxon signed-rank test. *P < .05 and **P < .01. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 A-C, Birch pollen–specific IgE (Fig 2, A), total IgG (Fig 2, B), and IgG4 (Fig 2, C) concentrations determined out of and during the birch pollen season (highlighted in gray) in patients with birch pollen allergy treated with SIT and after SIT (post-SIT). D, IgE/IgG ratio over the entire 54-month observation period. Median values are indicated by black lines. Discontinuities by dashed lines mark nonexistent data. Differences in pretreatment values compared with subsequent time points were analyzed by using the nonparametric Wilcoxon signed-rank test. *P < .05, **P < .01, and ***P < .001. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Bet v 1–specific IgG1 and IgG4 antibody levels (17 kDa) monitored in SIT-treated patients' sera by means of Western blotting at initiation of (I), end of (E), and after (P) SIT (m42 or m54 as indicated). M, Marker; Neg-C, serum of a healthy subject; Pos-C, serum of a patient with birch pollen allergy; Tris-C, buffer control. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 4 A, Analysis of allergen-IgE complex formation in SIT-treated patients with birch pollen allergy by using the FAP assay. The data from all patients is expressed as a percentage of the pretreatment value. B, Inhibitory capacity of treatment-induced non-IgE antibodies evaluated by using the IgE-blocking factor assay. Data are shown as a ratio of IgE binding to allergen in the presence of allergen-specific non-IgE antibodies divided by IgE binding alone. Median values are indicated by black lines. Birch pollen seasons are highlighted in gray. Discontinuities by dashed lines mark nonexistent data. Differences in pretreatment values compared with subsequent time points were analyzed by using the nonparametric Wilcoxon signed-rank test. *P < .05 and **P < .01. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig 5 A, Inverse relationship between allergen-specific IgG antibody concentrations and IgE-blocking factor in individual SIT-treated patients for up to 54 months. B, Comparison of mock-treated (IgG+) and IgG-depleted (IgG−) plasma samples from 5 patients with birch pollen allergy before initiation of SIT (pre-SIT) and at different time points (months 6, 18, 24, 30, and 36) during SIT, as evaluated by using ImmunoCAP analysis. C, IgE-blocking factor analysis of mock-treated (IgG+) and IgG-depleted (IgG−) plasma samples of 5 SIT-treated patients before initiation of treatment (pre-SIT) and during SIT. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

7 Fig E1 Specific IL-5 (A), IFN-γ (B), and IL-10 (C) production by PBMCs stimulated with rBet v 1. Cytokine levels were measured during 30 months (circles; m0-m30) of specific SIT and a post-SIT phase showing individual results at the last visit after termination of treatment (squares, month 42; triangles, month 54). Median values are indicated by black lines. Birch pollen seasons are highlighted in gray. Differences between initiation of SIT and during/after SIT were analyzed by using the nonparametric Wilcoxon signed-rank test. *P < .05 and **P < .01. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

8 Fig E2 Bet v 1–specific IgE antibody concentrations determined out of and during the birch pollen season (highlighted in gray) in patients with birch pollen allergy treated with SIT and after cessation of treatment (post-SIT). Median values are indicated by black lines. Discontinuities by dashed lines mark nonexistent data. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

9 Fig E3 Birch pollen–specific IgE/IgG4 ratios determined out of and during the birch pollen season (highlighted in gray) in patients with birch pollen allergy treated with SIT and after cessation of treatment (post-SIT). Median values are indicated by black lines. Discontinuities by dashed lines mark nonexistent data. Differences in pretreatment values compared with subsequent time points were analyzed by using the nonparametric Wilcoxon signed-rank test. *P < .05, **P < .01, and ***P < .001. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

10 Fig E4 nBet v 1–specific (A) and birch pollen extract–specific IgG1 and IgG4 antibody levels (B) monitored in SIT-treated patients' sera by means of Western blotting. Concomitant alterations in IgG1 and IgG4 levels were detectable comparing initiation of (I), end of (E), and time points after (P) SIT (month 42 or 54, as indicated). M, Marker; Neg-C, serum of a healthy subject; Pos-C, serum of a patient with birch pollen allergy; Tris-C, buffer control. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Birch pollen immunotherapy results in long-term loss of Bet v 1–specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies "

Similar presentations

Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy  Erik Wambre, PhD, Jonathan.

Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy  Erik Wambre, PhD, Jonathan.
Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.
Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies  Marija Geroldinger-Simic, MD, Thomas Zelniker,

Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies  Marija Geroldinger-Simic, MD, Thomas Zelniker,
Cor a 1–reactive T cells and IgE are predominantly cross-reactive to Bet v 1 in patients with birch pollen–associated food allergy to hazelnut  Claudia.

Cor a 1–reactive T cells and IgE are predominantly cross-reactive to Bet v 1 in patients with birch pollen–associated food allergy to hazelnut  Claudia.
Kuan-Wei Chen, PhD, Katharina Blatt, MSc, Wayne R

Kuan-Wei Chen, PhD, Katharina Blatt, MSc, Wayne R
High-titer IgE antibody specific for pollen allergens in northern California is associated with both wheezing and total serum IgE  Elizabeth A. Erwin,

High-titer IgE antibody specific for pollen allergens in northern California is associated with both wheezing and total serum IgE  Elizabeth A. Erwin,
Exploring the repertoire of IgE-binding self-antigens associated with atopic eczema  Sabine Zeller, MSc, Claudio Rhyner, PhD, Norbert Meyer, MD, Peter.

Exploring the repertoire of IgE-binding self-antigens associated with atopic eczema  Sabine Zeller, MSc, Claudio Rhyner, PhD, Norbert Meyer, MD, Peter.
Reduced TH1/TH17 CD4 T-cell numbers are associated with impaired purified protein derivative–specific cytokine responses in patients with HIV-1 infection 

Reduced TH1/TH17 CD4 T-cell numbers are associated with impaired purified protein derivative–specific cytokine responses in patients with HIV-1 infection 
Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE  Eva-Maria Varga, MD, Fahima Kausar, MSc, Werner.

Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE  Eva-Maria Varga, MD, Fahima Kausar, MSc, Werner.
Designing hypoallergenic derivatives for allergy treatment by means of in silico mutation and screening  Theresa Thalhamer, PhD, Heidi Dobias, MSc, Tatjana.

Designing hypoallergenic derivatives for allergy treatment by means of in silico mutation and screening  Theresa Thalhamer, PhD, Heidi Dobias, MSc, Tatjana.
Giant ragweed specific immunotherapy is not effective in a proportion of patients sensitized to short ragweed: Analysis of the allergenic differences.

Giant ragweed specific immunotherapy is not effective in a proportion of patients sensitized to short ragweed: Analysis of the allergenic differences.
Differential cytokine induction by the human skin–associated autoallergen thioredoxin in sensitized patients with atopic dermatitis and healthy control.

Differential cytokine induction by the human skin–associated autoallergen thioredoxin in sensitized patients with atopic dermatitis and healthy control.
Sputum indoleamine-2, 3-dioxygenase activity is increased in asthmatic airways by using inhaled corticosteroids  Kittipong Maneechotesuwan, MD, PhD, Sirinya.

Sputum indoleamine-2, 3-dioxygenase activity is increased in asthmatic airways by using inhaled corticosteroids  Kittipong Maneechotesuwan, MD, PhD, Sirinya.
Cor a 1–reactive T cells and IgE are predominantly cross-reactive to Bet v 1 in patients with birch pollen–associated food allergy to hazelnut  Claudia.

Cor a 1–reactive T cells and IgE are predominantly cross-reactive to Bet v 1 in patients with birch pollen–associated food allergy to hazelnut  Claudia.
Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule  Carine Metz-Favre, MD, Birgit Linhart, PhD, Margarete Focke-Tejkl, PhD,

Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule  Carine Metz-Favre, MD, Birgit Linhart, PhD, Margarete Focke-Tejkl, PhD,
Correlation of IgE/IgG4 milk epitopes and affinity of milk-specific IgE antibodies with different phenotypes of clinical milk allergy  Julie Wang, MD,

Correlation of IgE/IgG4 milk epitopes and affinity of milk-specific IgE antibodies with different phenotypes of clinical milk allergy  Julie Wang, MD,
Persistence of the IgE repertoire in birch pollen allergy

Persistence of the IgE repertoire in birch pollen allergy
The effects of house dust mite sublingual immunotherapy tablet on immunologic biomarkers and nasal allergen challenge symptoms  Natasha C. Gunawardana,

The effects of house dust mite sublingual immunotherapy tablet on immunologic biomarkers and nasal allergen challenge symptoms  Natasha C. Gunawardana,
Characterization of pollen antigen–induced IL-31 production by PBMCs in patients with allergic rhinitis  Mitsuhiro Okano, MD, Tazuko Fujiwara, BS, Takaya.

Characterization of pollen antigen–induced IL-31 production by PBMCs in patients with allergic rhinitis  Mitsuhiro Okano, MD, Tazuko Fujiwara, BS, Takaya.
Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies  Louisa K. James, PhD, Mohamed H. Shamji,

Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies  Louisa K. James, PhD, Mohamed H. Shamji,

Similar presentations

Ads by Google